Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 4,267 Shares

Key Points

• Insider sale: General Counsel Jonathan Allan sold 4,267 shares on March 17 at an average of $33.01 (about $140,854) and another 4,628 shares on March 18 at $31.34, reducing his stake by 11.31% to 33,464 shares valued near $1.10M.
• Mixed market signals: Analysts remain broadly bullish (consensus "Moderate Buy" with an average price target of $39.83), but a recent quarterly miss—EPS ($0.97) vs. $0.75 expected and revenue $1.4M vs. $5.3M expected—poses near-term downside while the stock trades around $33 (52-week range $5.35–$40.22).

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 4,267 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $33.01, for a total transaction of $140,853.67. Following the transaction, the general counsel owned 33,464 shares of the company's stock, valued at $1,104,646.64. The trade was a 11.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Jonathan Allan also recently made the following trade(s):

• On Wednesday, March 18th, Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total value of $145,041.52.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock traded up $2.17 during midday trading on Thursday, hitting $33.19. The company had a trading volume of 853,428 shares, compared to its average volume of 754,489. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $40.22. The stock has a market capitalization of $1.96 billion, a P/E ratio of 49.54 and a beta of 1.07. The company has a 50 day moving average of $32.61 and a 200 day moving average of $29.90.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Kestra Advisory Services LLC purchased a new position in shares of Stoke Therapeutics in the fourth quarter worth $26,000. Harbour Investments Inc. lifted its holdings in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock valued at $38,000 after purchasing an additional 898 shares in the last quarter. Generali Investments Management Co LLC purchased a new stake in shares of Stoke Therapeutics during the third quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company's stock worth $88,000 after buying an additional 658 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after buying an additional 1,668 shares in the last quarter.

Key Headlines Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed "buy" with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Analyst Ratings Changes

STOK has been the topic of a number of recent research reports. Wolfe Research initiated coverage on Stoke Therapeutics in a research note on Monday, February 23rd. They issued an "outperform" rating and a $40.00 target price on the stock. Guggenheim initiated coverage on shares of Stoke Therapeutics in a research note on Thursday, February 5th. They issued a "buy" rating and a $60.00 price target on the stock. HC Wainwright increased their price objective on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a "buy" rating in a research report on Monday, December 15th. BTIG Research restated a "buy" rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research note on Thursday. Finally, UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $39.83.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.